Regeneron Pharmaceuticals, Inc. (REGN) and Bayer HealthCare AG (BAY) Report Positive One-Year Results From Two Phase 3 Trials of EYLEA® (aflibercept) Injection for the Treatment of Diabetic Macular Edema (BioSpace)
Diabetes News Service
Regeneron Pharmaceuticals, Inc. (REGN) and Bayer HealthCare AG (BAY) Report Positive One-Year Results From Two Phase 3 Trials of EYLEA® (aflibercept) Injection for the Treatment of Diabetic Macular Edema (BioSpace)
For iPhone and iPad | For Android devices
For information about sponsorship and advertising please contact our editor-in-chief Jim Young jim@glycosmedia.com
Website by Wired up Wales